In vivo manifestation of Notch related phenotypes in zebrafish treated with Alzheimer's amyloid reducing γ-secretase inhibitors

Ting Yang, Dilyara Arslanova, Xiaoyin Xu, Yue Ming Li, Weiming Xia

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

γ-Secretase is responsible for the final cleavage of amyloid precursor protein to generate the amyloid-β protein, the major component of plaques in the brains of Alzheimer's disease patients. γ-Secretase inhibitors (GSI) have been explored for therapeutic inhibition of amyloid β protein generation, but mechanistic toxicity has been documented because of its blockage of γ-secretase cleavage of several dozens of substrates including Notch. This becomes the primary obstacle for most inhibitors during the pre-clinical development and the main concern for several compounds in the clinical trials. To predict potential side effects related to Notch signaling, we examined global effect of GSIs in vertebrate animal zebrafish. We have used two potent GSIs (GSI A and GSI 18) with a sub-μM effective concentration for 50% amyloid β protein inhibition (EC50). Zebrafish embryos were treated with GSI A, 18 or a well characterized GSI N-[N-(3,5-difluorophenacetyl- l-alanyl)]-S-phenylglycine t-butyl ester (DAPT), and transparent animals were examined for up to 7 days. GSI A had less abnormal phenotype in zebrafish, compared to GSI 18-treated embryos that displayed curved tails, a loss of pigmentation, and reduced swim bladder and heart rate. To understand mechanistic effect at the molecular level, we examined Notch signaling in these GSI-treated zebrafish. Notch phenotypes were observed in embryos treated with 50 and 10 μM GSI 18, but not with 10 μM GSI A. In accordance, in situ hybridization with a probe against Notch target gene her6 showed a weaker staining in embryos treated with 10 μM GSI 18 than those treated with 10 μM GSI A. In conclusion, phenotypic profile in whole animals offers important information on Notch related pathways and provides prediction of safe compounds during early development stages of therapeutic GSIs.

Original languageEnglish (US)
Pages (from-to)1200-1209
Number of pages10
JournalJournal of Neurochemistry
Volume113
Issue number5
DOIs
StatePublished - Jun 1 2010
Externally publishedYes

Fingerprint

Amyloidogenic Proteins
Amyloid Precursor Protein Secretases
Zebrafish
Amyloid
Animals
Embryonic Structures
Phenotype
Amyloid beta-Protein Precursor
Toxicity
Brain
Pigmentation
Esters
Brain Diseases
Genes
In Situ Hybridization
Vertebrates
Tail
Alzheimer Disease
Urinary Bladder
Heart Rate

Keywords

  • Alzheimer
  • Amyloid
  • Notch
  • Secretase
  • Zebrafish

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

In vivo manifestation of Notch related phenotypes in zebrafish treated with Alzheimer's amyloid reducing γ-secretase inhibitors. / Yang, Ting; Arslanova, Dilyara; Xu, Xiaoyin; Li, Yue Ming; Xia, Weiming.

In: Journal of Neurochemistry, Vol. 113, No. 5, 01.06.2010, p. 1200-1209.

Research output: Contribution to journalArticle

Yang, Ting ; Arslanova, Dilyara ; Xu, Xiaoyin ; Li, Yue Ming ; Xia, Weiming. / In vivo manifestation of Notch related phenotypes in zebrafish treated with Alzheimer's amyloid reducing γ-secretase inhibitors. In: Journal of Neurochemistry. 2010 ; Vol. 113, No. 5. pp. 1200-1209.
@article{79a54c5a79834071b9d79490288b0e64,
title = "In vivo manifestation of Notch related phenotypes in zebrafish treated with Alzheimer's amyloid reducing γ-secretase inhibitors",
abstract = "γ-Secretase is responsible for the final cleavage of amyloid precursor protein to generate the amyloid-β protein, the major component of plaques in the brains of Alzheimer's disease patients. γ-Secretase inhibitors (GSI) have been explored for therapeutic inhibition of amyloid β protein generation, but mechanistic toxicity has been documented because of its blockage of γ-secretase cleavage of several dozens of substrates including Notch. This becomes the primary obstacle for most inhibitors during the pre-clinical development and the main concern for several compounds in the clinical trials. To predict potential side effects related to Notch signaling, we examined global effect of GSIs in vertebrate animal zebrafish. We have used two potent GSIs (GSI A and GSI 18) with a sub-μM effective concentration for 50{\%} amyloid β protein inhibition (EC50). Zebrafish embryos were treated with GSI A, 18 or a well characterized GSI N-[N-(3,5-difluorophenacetyl- l-alanyl)]-S-phenylglycine t-butyl ester (DAPT), and transparent animals were examined for up to 7 days. GSI A had less abnormal phenotype in zebrafish, compared to GSI 18-treated embryos that displayed curved tails, a loss of pigmentation, and reduced swim bladder and heart rate. To understand mechanistic effect at the molecular level, we examined Notch signaling in these GSI-treated zebrafish. Notch phenotypes were observed in embryos treated with 50 and 10 μM GSI 18, but not with 10 μM GSI A. In accordance, in situ hybridization with a probe against Notch target gene her6 showed a weaker staining in embryos treated with 10 μM GSI 18 than those treated with 10 μM GSI A. In conclusion, phenotypic profile in whole animals offers important information on Notch related pathways and provides prediction of safe compounds during early development stages of therapeutic GSIs.",
keywords = "Alzheimer, Amyloid, Notch, Secretase, Zebrafish",
author = "Ting Yang and Dilyara Arslanova and Xiaoyin Xu and Li, {Yue Ming} and Weiming Xia",
year = "2010",
month = "6",
day = "1",
doi = "10.1111/j.1471-4159.2010.06681.x",
language = "English (US)",
volume = "113",
pages = "1200--1209",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - In vivo manifestation of Notch related phenotypes in zebrafish treated with Alzheimer's amyloid reducing γ-secretase inhibitors

AU - Yang, Ting

AU - Arslanova, Dilyara

AU - Xu, Xiaoyin

AU - Li, Yue Ming

AU - Xia, Weiming

PY - 2010/6/1

Y1 - 2010/6/1

N2 - γ-Secretase is responsible for the final cleavage of amyloid precursor protein to generate the amyloid-β protein, the major component of plaques in the brains of Alzheimer's disease patients. γ-Secretase inhibitors (GSI) have been explored for therapeutic inhibition of amyloid β protein generation, but mechanistic toxicity has been documented because of its blockage of γ-secretase cleavage of several dozens of substrates including Notch. This becomes the primary obstacle for most inhibitors during the pre-clinical development and the main concern for several compounds in the clinical trials. To predict potential side effects related to Notch signaling, we examined global effect of GSIs in vertebrate animal zebrafish. We have used two potent GSIs (GSI A and GSI 18) with a sub-μM effective concentration for 50% amyloid β protein inhibition (EC50). Zebrafish embryos were treated with GSI A, 18 or a well characterized GSI N-[N-(3,5-difluorophenacetyl- l-alanyl)]-S-phenylglycine t-butyl ester (DAPT), and transparent animals were examined for up to 7 days. GSI A had less abnormal phenotype in zebrafish, compared to GSI 18-treated embryos that displayed curved tails, a loss of pigmentation, and reduced swim bladder and heart rate. To understand mechanistic effect at the molecular level, we examined Notch signaling in these GSI-treated zebrafish. Notch phenotypes were observed in embryos treated with 50 and 10 μM GSI 18, but not with 10 μM GSI A. In accordance, in situ hybridization with a probe against Notch target gene her6 showed a weaker staining in embryos treated with 10 μM GSI 18 than those treated with 10 μM GSI A. In conclusion, phenotypic profile in whole animals offers important information on Notch related pathways and provides prediction of safe compounds during early development stages of therapeutic GSIs.

AB - γ-Secretase is responsible for the final cleavage of amyloid precursor protein to generate the amyloid-β protein, the major component of plaques in the brains of Alzheimer's disease patients. γ-Secretase inhibitors (GSI) have been explored for therapeutic inhibition of amyloid β protein generation, but mechanistic toxicity has been documented because of its blockage of γ-secretase cleavage of several dozens of substrates including Notch. This becomes the primary obstacle for most inhibitors during the pre-clinical development and the main concern for several compounds in the clinical trials. To predict potential side effects related to Notch signaling, we examined global effect of GSIs in vertebrate animal zebrafish. We have used two potent GSIs (GSI A and GSI 18) with a sub-μM effective concentration for 50% amyloid β protein inhibition (EC50). Zebrafish embryos were treated with GSI A, 18 or a well characterized GSI N-[N-(3,5-difluorophenacetyl- l-alanyl)]-S-phenylglycine t-butyl ester (DAPT), and transparent animals were examined for up to 7 days. GSI A had less abnormal phenotype in zebrafish, compared to GSI 18-treated embryos that displayed curved tails, a loss of pigmentation, and reduced swim bladder and heart rate. To understand mechanistic effect at the molecular level, we examined Notch signaling in these GSI-treated zebrafish. Notch phenotypes were observed in embryos treated with 50 and 10 μM GSI 18, but not with 10 μM GSI A. In accordance, in situ hybridization with a probe against Notch target gene her6 showed a weaker staining in embryos treated with 10 μM GSI 18 than those treated with 10 μM GSI A. In conclusion, phenotypic profile in whole animals offers important information on Notch related pathways and provides prediction of safe compounds during early development stages of therapeutic GSIs.

KW - Alzheimer

KW - Amyloid

KW - Notch

KW - Secretase

KW - Zebrafish

UR - http://www.scopus.com/inward/record.url?scp=77951905218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951905218&partnerID=8YFLogxK

U2 - 10.1111/j.1471-4159.2010.06681.x

DO - 10.1111/j.1471-4159.2010.06681.x

M3 - Article

C2 - 20345767

AN - SCOPUS:77951905218

VL - 113

SP - 1200

EP - 1209

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 5

ER -